Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more
Shanghai Haohai Biological Technology Co. Ltd (5HB) - Total Liabilities
Latest total liabilities as of June 2025: €1.30 Billion EUR
Based on the latest financial reports, Shanghai Haohai Biological Technology Co. Ltd (5HB) has total liabilities worth €1.30 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Haohai Biological Technology Co. Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Haohai Biological Technology Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Haohai Biological Technology Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Shuangyuan Technology Co. Ltd. A
SHG:688623
|
China | CN¥508.49 Million |
|
Suzhou Yangtze New Materials
SHE:002652
|
China | CN¥197.11 Million |
|
Puma Biotechnology Inc
NASDAQ:PBYI
|
USA | $85.96 Million |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
China | CN¥393.42 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥1.62 Billion |
|
HealthCare Inc
PINK:HLTC
|
USA | $1.11 Billion |
|
Deutsche EuroShop AG
PINK:DUSCF
|
USA | $2.77 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Haohai Biological Technology Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Haohai Biological Technology Co. Ltd (2016–2024)
The table below shows the annual total liabilities of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.20 Billion | +10.67% |
| 2023-12-31 | €1.09 Billion | +9.92% |
| 2022-12-31 | €990.02 Million | +11.23% |
| 2021-12-31 | €890.07 Million | +57.69% |
| 2020-12-31 | €564.46 Million | +13.23% |
| 2019-12-31 | €498.52 Million | -17.04% |
| 2018-12-31 | €600.90 Million | -15.20% |
| 2017-12-31 | €708.59 Million | +0.15% |
| 2016-12-31 | €707.55 Million | -- |